Nicox, Ocumension sign license agreement for blepharitis treatment

Nicox has entered into an exclusive license agreement with Ocumension Therapeutics for NCX 4251, the company’s blepharitis treatment candidate, according to a press release.

Under the agreement, which includes a territory comprised of mainland China, Hong Kong, Macau and Taiwan, Nicox will receive an upfront payment of 2 million euros and may receive development and sales milestones of up to 10 million euros. Ocumension will be responsible for development activities for the approval of NCX 4251 in the territory, the release said.

“Our strategy is to retain rights and associated potential revenues for our product candidates NCX 470 and NCX 4251 in the U.S. and key European markets and to partner in other regions to maximize the value of our product pipeline,” Gavin Spencer, Nicox chief business officer, said in the release.

Nicox has entered into an exclusive license agreement with Ocumension Therapeutics for NCX 4251, the company’s blepharitis treatment candidate, according to a press release.

Under the agreement, which includes a territory comprised of mainland China, Hong Kong, Macau and Taiwan, Nicox will receive an upfront payment of 2 million euros and may receive development and sales milestones of up to 10 million euros. Ocumension will be responsible for development activities for the approval of NCX 4251 in the territory, the release said.

“Our strategy is to retain rights and associated potential revenues for our product candidates NCX 470 and NCX 4251 in the U.S. and key European markets and to partner in other regions to maximize the value of our product pipeline,” Gavin Spencer, Nicox chief business officer, said in the release.